NYSE:PFEPharmaceuticals
Pfizer (PFE) Could Be 13% Undervalued On Mixed Oncology News And CFO Change
Pfizer (PFE) is in focus after investors were hit with mixed oncology news, a planned CFO transition, and fresh questions around its pipeline, all set against the backdrop of patent expirations and restructuring efforts.
See our latest analysis for Pfizer.
At a share price of $24.29, Pfizer has seen weaker momentum in recent months, with a 30 day share price return of 7.22% and a 90 day share price return of 12.53% despite oncology updates, legal clarity around Paxlovid, and a confirmed...